These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

2115 related items for PubMed ID: 18928543

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Expression of epidermal growth factor receptor and c-erbB2 during the development of tamoxifen resistance in human breast cancer.
    Newby JC, Johnston SR, Smith IE, Dowsett M.
    Clin Cancer Res; 1997 Sep; 3(9):1643-51. PubMed ID: 9815855
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Oligonucleotide microarray analysis of estrogen receptor alpha-positive postmenopausal breast carcinomas: identification of HRPAP20 and TIMELESS as outstanding candidate markers to predict the response to tamoxifen.
    Tozlu-Kara S, Roux V, Andrieu C, Vendrell J, Vacher S, Lazar V, Spyratos F, Tubiana-Hulin M, Cohen P, Dessen P, Lidereau R, Bièche I.
    J Mol Endocrinol; 2007 Oct; 39(4):305-18. PubMed ID: 17909269
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Low levels of estrogen receptor beta protein predict resistance to tamoxifen therapy in breast cancer.
    Hopp TA, Weiss HL, Parra IS, Cui Y, Osborne CK, Fuqua SA.
    Clin Cancer Res; 2004 Nov 15; 10(22):7490-9. PubMed ID: 15569979
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Microtubule-associated protein-tau is a bifunctional predictor of endocrine sensitivity and chemotherapy resistance in estrogen receptor-positive breast cancer.
    Andre F, Hatzis C, Anderson K, Sotiriou C, Mazouni C, Mejia J, Wang B, Hortobagyi GN, Symmans WF, Pusztai L.
    Clin Cancer Res; 2007 Apr 01; 13(7):2061-7. PubMed ID: 17404087
    [Abstract] [Full Text] [Related]

  • 12. High tumoral levels of Kiss1 and G-protein-coupled receptor 54 expression are correlated with poor prognosis of estrogen receptor-positive breast tumors.
    Marot D, Bieche I, Aumas C, Esselin S, Bouquet C, Vacher S, Lazennec G, Perricaudet M, Kuttenn F, Lidereau R, de Roux N.
    Endocr Relat Cancer; 2007 Sep 01; 14(3):691-702. PubMed ID: 17914099
    [Abstract] [Full Text] [Related]

  • 13. Outcome prediction for estrogen receptor-positive breast cancer based on postneoadjuvant endocrine therapy tumor characteristics.
    Ellis MJ, Tao Y, Luo J, A'Hern R, Evans DB, Bhatnagar AS, Chaudri Ross HA, von Kameke A, Miller WR, Smith I, Eiermann W, Dowsett M.
    J Natl Cancer Inst; 2008 Oct 01; 100(19):1380-8. PubMed ID: 18812550
    [Abstract] [Full Text] [Related]

  • 14. Estrogen receptor beta expression is associated with tamoxifen response in ERalpha-negative breast carcinoma.
    Gruvberger-Saal SK, Bendahl PO, Saal LH, Laakso M, Hegardt C, Edén P, Peterson C, Malmström P, Isola J, Borg A, Fernö M.
    Clin Cancer Res; 2007 Apr 01; 13(7):1987-94. PubMed ID: 17404078
    [Abstract] [Full Text] [Related]

  • 15. An ER activity profile including ER, PR, Bcl-2 and IGF-IR may have potential as selection criterion for letrozole or tamoxifen treatment of patients with advanced breast cancer.
    Henriksen KL, Rasmussen BB, Lykkesfeldt AE, Møller S, Ejlertsen B, Mouridsen HT.
    Acta Oncol; 2009 Apr 01; 48(4):522-31. PubMed ID: 19173092
    [Abstract] [Full Text] [Related]

  • 16. Prognostic impact of tumour-specific HMG-CoA reductase expression in primary breast cancer.
    Borgquist S, Jögi A, Pontén F, Rydén L, Brennan DJ, Jirström K.
    Breast Cancer Res; 2008 Apr 01; 10(5):R79. PubMed ID: 18808688
    [Abstract] [Full Text] [Related]

  • 17. Tissue inhibitors of metalloproteinase expression in human breast cancer: TIMP-3 is associated with adjuvant endocrine therapy success.
    Span PN, Lindberg RL, Manders P, Tjan-Heijnen VC, Heuvel JJ, Beex LV, Sweep CG.
    J Pathol; 2004 Apr 01; 202(4):395-402. PubMed ID: 15095266
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. [Factors predicting failure of adjuvant hormonotherapy of breast carcinoma. A study in tamoxifen treated patients].
    Petráková K, Nenutil R, Grell P, Fabian P, Zichová I, Svoboda M, Palácová M, Vyzula R.
    Klin Onkol; 2008 Apr 01; 21(5):303-8. PubMed ID: 19202962
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 106.